SAINT LAURENT, Quebec, Aug. 22, 2013 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) ("IntelGenx") today announced it has received a Paragraph IV Certification Letter from Wockhardt Bio AG, advising of the submission of an Abbreviated New Drug Application ("ANDA") to the U.S. Food and Drug Administration ("FDA") requesting authorization to manufacture and market generic versions of Forfivo XL™ ("Forfivo") 450 mg capsules in the United States.
Help employers find you! Check out all the jobs and post your resume.
